Get started
Windtree Therapeutics, Inc.Windtree Therapeutics, Inc.Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

WINT trade ideas

WINT: Assessing Recovery Potential After Significant DeclineAfter hitting $14.58, Windtree Therapeutics, Inc. has faced a substantial decline, now approaching its all-time low of $2.55. This sharp drop raises questions about the company's potential for recovery. Investors are watching closely for signs of a rebound and whether indicators will signal a buying opportunity. Market conditions, company developments, and broader economic factors will play a crucial role in determining if Windtree can regain momentum. Analysts and traders will be keen to spot any bullish trends or shifts in sentiment that could suggest a turnaround. As the situation evolves, it will be important to monitor key metrics and news related to the company for a clearer picture of its prospects.
NASDAQ:WINTShort
by Joekenstein7
WINT reverse split pumpA reverse split pump in the small cap stock market refers to a situation where a company, typically with a low stock price, undergoes a reverse stock split in order to artificially inflate its stock price. Here's how it typically works: Low Stock Price: Small cap stocks often have low prices per share, sometimes trading for just a few cents. This low price can make the stock less attractive to investors and may even lead to delisting from stock exchanges that have minimum price requirements. Reverse Stock Split: To combat the low stock price and possibly meet exchange listing requirements, the company executes a reverse stock split. In a reverse split, existing shares are combined to reduce the total number of outstanding shares, thereby increasing the price per share proportionally. For example, in a 1-for-10 reverse split, every 10 shares a shareholder owns are converted into 1 share, effectively increasing the price by a factor of 10. Pump: After the reverse split, there may be efforts to artificially boost the stock price, creating what is known as a "pump." This can involve various tactics, such as promotional campaigns, exaggerated press releases, or even coordinated buying by groups of investors. The goal is to create a perception of increased value and generate buying interest in the stock.
NASDAQ:WINTLong
by AntonioNaVi
WINT - Catalyst on 08/31/2024 - Volume is increasingWindtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug-delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products. Please note: This is not financial advice. Key Update: Upcoming Event on August 31, 2024 Share Float: The current share float is only 7.38 million. Volume Trends: Recently, there has been an increase in trading volume. Relative Volume: As of April 12, 2024, the relative volume was 3.06. Market Sentiment: It's crucial to monitor the overall market sentiment. If the market remains bullish, the strategy could be favorable. However, be cautious of potential corrections which could impact this play. Key Levels to Watch: Resistance Level: Keep an eye on the $0.60 price level; breaking this could lead to further upward movement. Profit-Taking: Consider taking partial profits at various levels to secure gains. Stop-Loss: Set a stop-loss below $0.35 to limit potential losses. Target Prices: Potential target prices around approximately $0.85. Additional Insights: Most of the detailed information can be found on the accompanying chart. Trading Strategy: Proceed with caution and make informed decisions based on comprehensive chart analysis and market conditions.
NASDAQ:WINTLong
by meitshels_smell_trades
WINT - nov 26 : WINT - nov 26 : Wind-tree Is Studying Istaroxime in Early Cardiogenic Shock Patients WARRINGTON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the results of U.S. hospital claims data analysis showing hospital inpatient mortality and length of hospital stay for cardiogenic shock patients. Cardiogenic shock is a serious condition that occurs when the heart cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs. Cardiogenic shock is a medical emergency and needs to be treated immediately.1 There is a lack of satisfactory pharmacological intervention to reverse the conditions as available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal dysfunction and even increases in mortality that limit their usefulness and position them as “rescue medicines” for severe cases. U.S. hospital claims data reveals that inpatient mortality for cardiogenic shock patients was 30% in 2020.2 To help explain the relative severity of cardiogenic shock, the acute myocardial infarction (e.g. “heart attack”) mortality rate in the U.S. was 5% in 2020.3 The analysis, along with previously reported primary market research with 100 U.S. cardiologists noting a high need for new therapies and their high likelihood of using an agent with istaroxime’s observed clinical profile further reveals the need for improved pharmacologic innovation for cardiogenic shock patients. Additionally, U.S. hospital claims data was assessed to determine length of stay in the hospital for cardiogenic shock patients. The average length of stay for patients with cardiogenic shock was 19.6 days with a median of 10 days in 2020.4 According to the Agency for Healthcare Research and Quality (AHRQ), the U.S. national average for a hospital stay of any disease was 4.6 days in 2020.5
NASDAQ:WINT
by NART11
WINT - Ready to Double 😵-Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading higher by 32% at $2.63 in Friday's premarket session after Oppenheimer initiated coverage on the stock with an Outperform rating and an $8 price target. -Windtree Therapeutics is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. The company's technology platform includes a synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactant without invasive procedures. -Windtree's development program utilizing its proprietary technology platform is AEROSURF that is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products.
NASDAQ:WINTLong
by caldooninvestment
13
Windtree Therapeutics Inc 🧙Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes a synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactant without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF that is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products. If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:WINTLong
by trading_as_bus
1